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Abstract Injection therapy and denervation procedures
are commonly used in the management of chronic low-back
pain (LBP) despite uncertainty regarding their effectiveness
and safety. To provide an evaluation of the current evidence
associated with the use of these procedures, a systematic
review was performed. Existing systematic reviews were
screened, and the Cochrane Back Review Group trial reg-
ister was searched for randomized controlled trials (RCTs)
fulﬁlling the inclusion criteria. Studies were included if they
recruited adults with chronic LBP, evaluated the use of
injection therapy or denervation procedures and measured
at least one clinically relevant outcome (such as pain or
functional status). Two review authors independently
assessed studies for eligibility and risk of bias (RoB). A
meta-analysis was performed with clinically homogeneous
studies, and the GRADE approach was used to determine
the quality of evidence. In total, 27 RCTs were included, 14
on injection therapy and 13 on denervation procedures. 18
(66%) of the studies were determined to have a low RoB.
Because of clinical heterogeneity, only two comparisons
could be pooled. Overall, there is only low to very low
quality evidence to support the use of injection therapy and
denervation procedures over placebo or other treatments for
patients with chronic LBP. However, it cannot be ruled out
that in carefully selected patients, some injection therapy or
denervation procedures may be of beneﬁt.
Keywords Injection  Back pain  Denervation 
Review
Introduction
Chronic low-back pain (LBP) is related to disability and
work absence and accounts for high social and health care
costs in western societies [1]. The management of chronic
LBP comprises a range of different intervention strategies
including surgery, pharmacological interventions and non-
medical interventions such as exercise, behavioural therapy
and alternative therapies. Non-surgical interventions, such
as injection therapy and denervation procedures, have
rapidly increasing rates of utilization and associated costs
[2]. Injection therapy for chronic LBP involves injections
of medications, irritants, or proteolytic enzymes into soft
tissues outside or within the spine. Denervation procedures
involve the application of various types of thermal or
radiofrequency energy within the spine.
Over the past years, a substantial number of randomized
clinical trials have been published on injection therapy and
denervation procedures. In order to appropriately evaluate
the effects of these interventions in a systematic review, it
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neous with regard to study population, indications, inter-
ventions and different anatomical structures being targeted,
controls, outcome measures and follow-up. Based on the
available literature, this overview presents the current
evidence on injections into and outside the spine and
radiofrequency or thermal denervation procedures for non-
speciﬁc chronic LBP.
Objectives
The objective of this review was to determine the effec-
tiveness of injection therapy (including injections into soft
tissues outside or within the spine and chemonucleolysis),
and radiofrequency or thermal denervation procedures for
chronic LBP.
Criteria for considering studies for this review
Types of studies
Only randomized controlled trials with at least 1 day of
follow-up were considered in this systematic review.
Types of participants
In order to be included in this review, participants of the
randomized controlled trials (RCTs) must fulﬁl the fol-
lowing inclusion criteria: adult subjects (C18 years of age)
with chronic ([12 weeks duration) LBP (including sub-
jects with radiculopathy or any other non-speciﬁc degene-
rative pathology, such as osteoarthritis). Exclusion criteria
were (1) trials including subjects with speciﬁc LBP caused
by pathological entities, such as vertebral spinal stenosis,
ankylosing spondylitis, scoliosis, or coccydynia; (2) post-
partum LBP or pelvic pain due to pregnancy; (3) post-
operative studies; (4) prevention studies; and (5) abstracts
or non-published studies.
Types of interventions
RCTs studying the following interventions were included
in this overview: injection of medications or proteolytic
enzymes (chemonucleolysis); and radiofrequency or ther-
mal denervation procedures. All anatomical sites subject to
injection therapy (intervertebral disc, facet joint, epidural
space, intramuscular) and denervation procedures (facet
joint, intervertebral disc, spinal nerves) for LBP were
included. Additional interventions were allowed in all
studies if there was a contrast for the injection therapy or
denervation procedure in the study.
Types of outcome measures
To be included at least one of the following outcome
measures should have been measured in the RCT: pain
intensity [e.g. visual analog scale (VAS), numerical rating
scale (NRS), McGill pain questionnaire], back speciﬁc
functional status [e.g. Roland–Morris Disability Question-
naire, Oswestry Disability Index (ODI)], perceived recov-
ery (e.g. overall improvement), and return to work (e.g.
return to work status, sick leave days). The primary out-
comes for this review were pain and functional status.
Search methods for identiﬁcation of studies
Existing systematic reviews for the interventions were
screened for studies fulﬁlling the inclusion criteria [3–6].
Then, the literature was searched in the Cochrane Back
Review Group (CBRG) trial register from the last date
onward for each of the interventions up to November 17,
2009.
References of relevant studies were screened and
experts were approached in order to identify additional
primary studies not identiﬁed in the previous steps. The
language was limited to English, Dutch, French and Ger-
man, because these are the languages that the authors are
able to read and understand. The search strategy outlined
by the CBRG was followed [7].
Methods of the review
Study selection
Two authors (NH, TK) independently screened the
abstracts and titles retrieved by the search strategy and
applied the inclusion criteria to all relevant abstracts. The
full text version of an article was obtained if the title and
abstract seemed to fulﬁll the inclusion criteria or if eligi-
bility of the study was unclear. All full text articles from
the existing reviews were compiled and independently
screened for inclusion criteria by the authors. Any dis-
agreements on study eligibility were resolved by discussion
and a consensus meeting.
Risk of bias assessment
Two authors (NH, TK) independently assessed the risk of
bias (RoB) of all eligible studies using the criteria list
advised by the CBRG, which consists of 11 items [7].
Items were scored as ‘positive’ if they fulﬁlled the criteria,
as ‘negative’ when there was a clear RoB, and as ‘incon-
clusive’ if there was insufﬁcient information. Differences
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A total score was computed by adding the number of
positive scores, and low RoB was deﬁned as fulﬁlling six
or more (more than 50%) of the 11 internal validity criteria.
Empirical evidence has shown that studies fulﬁlling \6
items report higher treatment effects than studies fulﬁlling
6 or more items [8].
Data extraction
A standardized form was used for data extraction which
included collection of descriptive data on the study popu-
lation and the type of intervention, as well as quantitative
data regarding the outcome measures. Data on the char-
acteristics of the study population (gender, age), type of
therapy and control treatment, adverse events and com-
plications were also collected.
Data analysis
If studies were clinically homogeneous regarding study
population, types of treatment, outcomes and measurement
instruments, a meta-analysis was performed. If possible,
the weighted mean difference (WMD) was calculated
because this improves the interpretability of the results. If a
WMD was not possible the standardized mean difference
(SMD) was calculated. If trials reported outcomes as
graphs, the mean scores and standard deviations (SD) were
estimated from these graphs. If SD were not reported, they
were calculated using the reported values of the conﬁdence
intervals, if possible. If the SD of the baseline score was
reported, we used the ratio between the baseline score and
SD to calculate the SD for other follow-up moments.
Finally, if none of these data were reported, an estimation
of the SD was based on study data (population and score)
of other studies. In order to correct for error introduced by
‘‘double-counting’’ of subjects of ‘‘shared’’ interventions
(i.e. 2 comparisons within 1 study that used the same
control group as contrast) in the meta-analyses, the number
of subjects in the control group was divided by the number
of comparisons that this one study added in the meta-
analyses. For the comparisons where studies were too
heterogeneous, no meta-analysis was performed.
Quality of the evidence
Grades of recommendation, assessment, development and
evaluation (GRADE) proﬁles were used to evaluate the
overall quality of the evidence and the strength of the rec-
ommendations [9]. The quality of the evidence for a speciﬁc
outcome was based upon ﬁve principal factors: (1) limita-
tions (for example due to study design), (2) inconsistency of
results, (3) indirectness (e.g. generalizability of the ﬁnd-
ings), (4) imprecision (e.g. sufﬁcient data) and (5) other
considerations, such as reporting bias. The overall quality
was considered to be high when multiple RCTs with a low
RoB provide consistent, generalizable, and precise data for
a particular outcome. The quality of the evidence was
downgraded by one level when one of the factors described
above was not met [9]. Single studies were considered
inconsistent and imprecise (i.e. sparse data) and provide
‘‘low quality evidence’’, which could be further down-
graded to ‘‘very low quality evidence’’ if there were also
limitations in design or indirectness. The following grading
of quality of the evidence was applied [10]:
High quality Further research is very unlikely to
change our conﬁdence in the estimate
of effect.
Moderate quality Further research is likely to have an
important impact on our conﬁdence in
the estimate of effect and may change
the estimate.
Low quality Further research is very likely to have
an important impact on our conﬁdence
in the estimate of effect and is likely to
change the estimate.
Very low quality We are very uncertain about the
estimate.
Results
Description of studies
Study selection
From three existing reviews a total of 83 references were
screened for eligibility. Of these 83 articles, 11 studies
fulﬁlled the inclusion criteria and were included in this
overview (Fig. 1). The most important reason for exclusion
was inclusion of acute or sub-acute patients in the study or
lack of information about the duration of the complaints
prior to the study. Additionally, 14 potentially relevant
titles and abstracts were identiﬁed in the CBRG trial reg-
ister for injection-related interventions and screened for
potential inclusion. All of these abstracts fulﬁlled the
inclusion criteria and were therefore included. Two addi-
tional studies were found by forward citation searching of
included studies.
In total 27 studies were included in this review. The
study characteristics of all included (Appendix 1) and
excluded studies (Appendix 2) are summarized in
appendices.
Eur Spine J (2010) 19:1425–1449 1427
123Injection therapy
Intervertebral disc One RCT was identiﬁed which eva-
luated injection therapy aimed at the intervertebral disc in
chronic LBP patients [11]. The authors compared chemo-
nucleolysis (intradiscal injection of chymopapain which
digests the nucleus pulposus) to discectomy in patients
with disc herniation which was conﬁrmed by myelography
[11]. This trial enrolled patients with both sub-acute and
chronic LBP, but presented selected outcomes for the
subgroup of patients (n = 58) with a duration of symptoms
[6 months.
Zygapophysial joints (facet joints) Eight trials, three of
which were placebo controlled [12–14], evaluated intra-
articular or peri-articular facet joint injections with
corticosteroids (methyl-prednisolone, triamcinolone, or
betamethasone) [12, 15], local anaesthetic (lidocaine,
bupivacaine, or lignocaine) [14], sodium hyaluronate [16],
Sarapin (a suspension of powdered pitcher plant in alkaline
solution) [17], or a combination of these [13, 18, 19]. Three
of these trials conﬁrmed that pain was originating from the
facet joint by including only patients with a positive
response to local anaesthetic nerve block [12, 17, 18]. One
trial used radiographic conﬁrmation of facet joint arthritis
as an inclusion criterion [16] while the remaining four trials
used clinical criteria (e.g. unilateral pain, pain with sus-
tained postures) to identify patients with facet joint pain
[13–15, 19].
Epidural space Three RCTs were identiﬁed that evalu-
ated injections of corticosteroids [20, 21] or anaesthetic
[22] into the epidural space. There were no placebo-con-
trolled trials of injections into the epidural space.
Full text articles included (n=25):
Intervertebral disc (n = 6) 
Zygapophysial joints (n = 14) 
Epidural space (n = 3)
Lumbar musculature (n = 1)
Forward citation tracking and
reference searching (n = 2) 
Excluded (n = 72) :
Not injection therapy (n = 23)
No contrast (n = 2) 
 LBP duration < 3 months (n = 45)
Postoperative patients (n = 2)
Search in CBRG trials register
(n = 14)
Total included studies (n = 27) 
Intervertebral disc (n = 7) 
Zygapophysial joints (n = 15) 
Epidural space (n = 3)
Lumbar musculature (n = 2)
Potentially relevant publications identified and screened from previous
systematic reviews (n = 83):
Staal 2008 (n = 18) 
Abdi 2007 (n = 25)
Gibson 2007 (n = 40)
Fig. 1 Flow diagram of
selection process of studies on
injection therapy for chronic
LBP
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zodiazepine [21], spinal endoscopy [20] or between ropi-
vacaine and bupivacaine [22]. One study excluded patients
with a previous history of spinal surgery [20].
Spinal muscles (local injections) Two RCTs were iden-
tiﬁed that evaluated local intramuscular injections for non-
speciﬁc chronic LBP. One study compared injections of
vitamin B12 with placebo [23], while the other compared
injections of botulinum toxin A with placebo [24].
Denervation procedures
Intervertebral disc Six RCTs were identiﬁed which
evaluated denervation procedures [25–30] for chronic LBP
targeted at or around the intervertebral disc. Five of the
trials only included patients with positive responses to
either analgesic [25] or provocative [26–29] discography.
Three trials evaluated the use of percutaneous intradiscal
radiofrequency thermocoagulation (PIRFT). PIRFT
involves the placement of an electrode or catheter into the
intervertebral disc and applying an alternating radiofre-
quency current to reduce nociceptive input from the disc.
Two of the trials were placebo controlled [25, 28], while
the other compared high- with low-intensity PIRFT [26].
Two trials were identiﬁed which compared the use of
intradiscal electrothermal therapy (IDET) with a placebo
[27, 29]. IDET is similar to PIRFT and involves the
insertion of an electrode into the annulus or nucleus of the
intervertebral disc and application of electrothermal energy
to alter the pain receptors.
One RCT evaluated radiofrequency denervation of the
ramus communicans nerve compared with placebo dener-
vation in patients who failed to respond to IDET [30]. This
denervation is performed outside the intervertebral disc,
unlike IDET and PIRFT.
Zygapophysial joints (facet joints) Six trials compared
radiofrequency denervation of the medial branch of the
dorsal ramus with a sham denervation procedure [31–36],
and one trial compared radiofrequency denervation of the
dorsal root ganglion with a sham procedure [37]. The trial
by Tekin and colleagues [34] included comparisons
between conventional, pulsed, and sham radiofrequency
denervation. All trials except one [32] included only
patients with a positive response (*50–80% pain relief) to
selective anaesthetic nerve blocks. The trial by Leclaire
and colleagues [32] included patients who experienced
signiﬁcant relief of their LBP for at least 24 h during the
week after intra-articular facet injections under ﬂuoros-
copy. This inclusion criterion was considered to be insuf-
ﬁciently sensitive and likely to have included patients with
pain of non-facet joint origin [32]. Therefore, this trial was
not included in the primary analysis, but a sensitivity
analysis was performed to evaluate the addition of this
study to the meta-analyses.
Risk of bias in included studies
The results of the RoB assessment are shown in Table 1.1 8
studies (66%) had a low RoB. All studies were described as
randomized; however, only nine studies (33%) used an
adequate randomization procedure in combination with an
adequate concealment of treatment allocation. In only four
studies (15%) co-interventions were avoided or similar
between groups. Many studies had acceptable compliance
(20 studies; 77%) or acceptable drop-out rates (21 studies;
77%) or both (15 studies; 58%).
Effects of intervention
Feasibility of statistical pooling
Asstatedinthemethodssection,statisticalpoolingwasonly
considered if subgroups of studies were clinically homoge-
neous, and the authors provided sufﬁcient information on
study characteristics, outcome measures, and study results.
After reviewing the included study characteristics, only two
treatment subgroups (IDET vs. placebo and facet joint
denervation vs. placebo) were sufﬁciently clinically homo-
geneous to perform statistical pooling (Table 2).
Injection therapy
Intervertebral disc
Chemonucleolysis versus other treatment In one RCT
with a high RoB, chemonucleolysis (via intradiscal chy-
mopapain injection) was compared with discectomy [11].
A subgroup of 68 patients had duration of symptoms
[6 months prior to the start of the trial. There was no
difference between groups in percentage of patients whose
pain had disappeared or improved (87 vs. 85%) 12 months
post-treatment. Within 12 months post-treatment, 25% of
the chemonucleolysis group were considered treatment
failures and underwent surgery.
There is very low quality evidence (1 RCT; n = 68;
limitations in design, inconsistency, imprecision) that
chemonucleolysis is no more effective than discectomy
over a long-term follow-up.
Zygapophyseal joint (facet joint)
Facet joint injections with corticosteroids versus pla-
cebo TwoRCTs,onewithlowRoB[12]andonewithhigh
RoB [13], compared the effects of facet joint injections with
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123corticosteroids to placebo injections. There was insufﬁcient
data on pain and functional status in the Lilius study [13]t o
allowforstatisticalpoolingofoutcomes.IntheCarettestudy
[12], no signiﬁcant differences were found between the
groups at 1 and 3 months for pain, functional status or self-
rated improvement. At the 6-month follow-up, signiﬁcant
differences were found in favour of the corticosteroid group
[12]. The high RoB study [13] compared intra-articular and
peri-capsular corticosteroid injections with placebo injec-
tions. No signiﬁcant differences between the groups were
reported for pain, disability or work attendance at either
short- or intermediate-term follow-ups [13]. No side effects
apart from transient pain were reported.
There is very low quality evidence (1 RCT; n = 97;
inconsistency, indirectness, imprecision) that there is no
signiﬁcant difference in effect between facet joint injections
with corticosteroids and placebo injections for short- to
intermediate-term pain relief and improvement of function.
Facet joint injections with corticosteroids versus other
treatment Five RCTs compared the effects of cortico-
steroids injections into and around the facet joints with
other treatments [15–19]. Because of the clinical hetero-
geneity of the reference treatments, pooling was deter-
mined to be unsuitable.
In a study with low RoB [19], intra-articular facet joint
injections with corticosteroids and lignocaine were com-
pared with facet nerve blocks using similar medication.
The facet joint injections provided slightly better pain relief
than facet nerve blocks, although statistical signiﬁcance
was only reached at 1 month, not immediately post-treat-
ment or after 3 months [19].
Two RCTs with high RoB compared intra-articular facet
joint corticosteroid injections with other treatments; one
compared facet joint injections with a mixture of local
anaesthetics and corticosteroids combined with a home
stretching exercise program with the home stretching
exercise program only [15]. No signiﬁcant post-treatment
differences between the groups were found for pain and
disability. The other trial compared the effects of facet joint
corticosteroid injections with intra-articular sodium hyal-
uronate injections. No signiﬁcant differences in pain relief,
disability and quality of life between the groups were found
at different follow-up points over a 6-month period [16].
One RCT with low RoB [18] compared the effects of
multiple medial branch blocks of corticosteroids combined
with local anaesthetics with multiple medial branch blocks
consisting of only local anaesthetics. No signiﬁcant differ-
ences between the groups were found at 3, 6 or 12 months
post-treatment. One RCT with high RoB [17] compared the
effects of multiple medial branch blocks of corticosteroids
combined with local anaesthetics and Sarapin with multiple
medial branch blocks consisting of local anaesthetics and
Sarapin. No signiﬁcant differences between the groups were
found for pain relief, overall health, functional status and
return-to-work over more than 2 years of follow-up.
There is low quality evidence (1 RCT; n = 86; incon-
sistency, imprecision) that intra-articular facet joint
Table 2 Pooled effect estimates for injection therapy and denervation procedures
Outcome title No. of
studies
No. of
participants
Statistical method Effect size
Comparison 01: IDET versus placebo for chronic non-speciﬁc LBP
01 Change in pain intensity from baseline
on SF-36 Bodily Pain Index (100-point).
Long-term follow-up (6 months)
2 111 Weighted mean difference
(ﬁxed) 95% CI
-7.84 [-14.96, -0.72]
02 Change in functional status from baseline
on Oswestry Disability Index (100-point).
Long-term follow-up (6 months)
2 111 Weighted mean difference
(ﬁxed) 95% CI
-4.93 [-10.11, 0.25]
Comparison 02: radiofrequency denervation of lumbar facet joints compared with placebo for chronic LBP
01 Change in pain intensity from baseline
on 100-point VAS. Short-term
follow-up (B4 weeks)
2 90 Weighted mean difference
(ﬁxed) 95% CI
-18.15 [-24.21, -12.09]
02 Change in pain intensity from baseline
on 100-point VAS. Intermediate-term
follow-up (1–6 months)
2 112 Weighted mean difference
(random) 95% CI
-9.29 [-22.57, 4.00]
03 Change in pain intensity from baseline
on 100-point VAS. Long-term
follow-up (6 months)
3 130 Weighted mean difference
(random) 95% CI
-6.99 [-14.73, 0.76]
04 Change in functional status from baseline
on Oswestry Disability Index.
Short-term follow-up (B4 weeks)
1 60 Weighted mean difference
(ﬁxed) 95% CI
-5.53 [-8.66, -2.40]
For forest plots and GRADE evidence proﬁles, see Appendix 3
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123injections are slightly more effective than facet nerve
blocks for pain relief in the intermediate term. There is
very low quality evidence (1 RCT; n = 70; limitations in
design, inconsistency, imprecision) that intra-articular facet
joint injections add no beneﬁt to a home exercise stretching
program in terms of pain and disability over the short term.
There is very low quality evidence (1 RCT; n = 60; limi-
tations in design, inconsistency, imprecision) that there is
no signiﬁcant difference in effect between intra-articular
facet joint corticosteroid injections and intra-articular
injections of sodium hyaluronate on pain and disability
over a long-term follow up. There is very low quality
evidence (1 RCT; n = 120; inconsistency, indirectness,
imprecision) that the addition of corticosteroids does not
increase the effectiveness of facet joint nerve blocks with
local anaesthetic. There is very low quality evidence
(1 RCT; n = 73; limitations in design, inconsistency,
indirectness, imprecision) that the addition of corticoste-
roids does not increase the effectiveness of facet joint nerve
blocks with anaesthetic and Sarapin in chronic LBP.
Facet joint injections with local anaesthetic versus
placebo One RCT with low RoB [14] compared intra-
articular facet joint injections with lidocaine to intra-
articular facet joint injections with saline. In both groups
these injections were followed by an injection of cortico-
steroid (cortivazol) near the joints. The lidocaine group had
signiﬁcantly higher pain relief post-treatment than the
saline group [14].
There is low quality evidence (1 RCT; n = 80; incon-
sistency, imprecision) that intra-articular facet joint injec-
tions with lidocaine combined with peri-articular
corticosteroid injections are more effective for short-term
pain relief than placebo.
Epidural space
Epidural corticosteroid injections versus other treat-
ments In an RCT with high RoB [21], an epidural
injection with a corticosteroid and dextrose solution was
compared with an intrathecal benzodiazepine with dextrose
injection. Two weeks and 2 months post-treatment, no
signiﬁcant differences between the groups were reported
for pain relief or general improvement.
One RCT with low RoB [20] compared caudal epidural
local anaesthetic and steroid injectionwith targeted epidural
local anaesthetic and steroid placement with a spinal endo-
scope. No signiﬁcant differences were found between the
groups for any of the outcome measures at any of the times.
In all patients in the endoscope group, post-treatment low-
back discomfortwasexperienced butthiswasnotpersistent.
There is very low quality evidence (2 RCTs; n = 88;
limitations in design, imprecision, inconsistency) that
epidural corticosteroid injection is not signiﬁcantly differ-
ent to benzodiazepine injection or targeted epidural place-
ment for pain relief over the short to intermediate term.
Epidural injections with local anaesthetics versus other
treatments One RCT with low RoB [22] compared the
effects of epidural blocks with ropivacaine with epidural
blocks with bupivacaine. Eight single shot epidural injec-
tions followed by active physiotherapy were performed in
all patients. There were no signiﬁcant differences found
between the groups in post-treatment analgesia. There were
three cases of short episodes of headache post-injection.
There is low quality evidence (1 RCT; n = 40; impre-
cision, inconsistency) that there is no signiﬁcant difference
in analgesia provided by blocks of ropivacaine or bupiva-
caine in the short term.
Lumbar musculature
Intramuscular injections with vitamin B12 versus pla-
cebo In one RCT with high RoB [23], the effects of
intramuscular vitamin B12 injections were compared with
intramuscular placebo injections. Post-treatment, there
were signiﬁcant improvements for pain and disability in
favour of the vitamin B12 group.
There is very low quality evidence (1 RCT; n = 60;
limitations in design, inconsistency, imprecision) that
intramuscular vitamin B12 injections are more effective
than intramuscular placebo injections for short-term pain
relief and improvement of function.
Intramuscular injections with botulinum toxin A versus
placebo In one RCT with low RoB, intramuscular
injections of botulinum toxin A were compared with
intramuscular placebo injections of saline [24]. At 3 weeks
follow-up, the degree of pain relief was signiﬁcantly dif-
ferent between groups in favour of the botulinum toxin A
group. At 8 weeks patients in the botulinum toxin A group
had signiﬁcantly more pain relief and better ODI scores
than the placebo group.
There is low quality evidence (1 RCT; n = 31; incon-
sistency, imprecision) that intramuscular botulinum toxin
A injections are more effective for pain relief in the short-
and intermediate-term than placebo.
Denervation procedures
Intervertebral disc
Percutaneous intradiscal radiofrequency thermocoagula-
tion versus placebo In one placebo-controlled trial
(n = 28) with low RoB, no signiﬁcant differences were
found between PIRFT and sham PIRFT in pain VAS
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come of overall treatment success 8 weeks post-treatment
[25]. In a second placebo-controlled trial (n = 20) with
low RoB, only follow-up data which were collected after 6
and 12 months post-treatment were reported [28]. No sig-
niﬁcant differences were seen between the PIRFT and
sham-PIRFT groups on pain intensity or functional status at
either of these time points. Because of the variability in the
timing of outcome measures between these two studies, a
decision was made not to pool the results.
A third trial (n = 37) with high RoB found minimal
improvement over 6 months on pain (VAS) and disability
(ODI) with both lower- and higher- intensity of PIRFT. No
signiﬁcant differences were found between the groups at
any of the follow-up assessments [26]. No complications or
adverse events were reported in the placebo-controlled
trials. One patient was excluded from the analysis of
Ercelen et al. [26] because of discitis.
There is low quality evidence (1 RCT; n = 28; incon-
sistency; imprecision) that there is no difference between
PIRFT and placebo in pain and functional status outcomes
over an intermediate term of follow-up. There is also low
quality evidence (1 RCT; n = 20; inconsistency; impreci-
sion) that there is no difference between PIRFT and pla-
cebo in pain and functional status outcomes over a long-
term follow-up.
Intradiscal electrothermal therapy versus placebo: pain
In patients with a positive response to provocative dis-
cography, two small (n = 55 and n = 56), low RoB, pla-
cebo-controlled randomized trials evaluated IDET and both
provided sufﬁcient data for pooling [27, 29]. Both studies
measured pain with the SF-36 Bodily Pain Index (100-
point scale). The Chi-square value for homogeneity of the
WMD was 0.09 (P[0.05), indicating statistical homoge-
neity among these studies.
There is low quality evidence (2 RCTs; n = 111; indi-
rectness, imprecision) that IDET is more effective than
placebo for pain relief over a long-term (6 months) follow-
up (WMD -7.84; 95% CI -14.96 to -0.72) (Table 2,
Analysis 01.01).
Intradiscal electrothermal therapy versus placebo: func-
tional status The same two RCTs [27, 29] provided ODI
scores on a 100-point scale which allowed statistical
pooling. The Chi-square value for homogeneity of the
WMD was 1.37 (P[0.05), indicating statistical homo-
geneity among these studies.
There is low quality evidence (2 RCTs; n = 111; indi-
rectness, imprecision) that IDET is no more effective than
placebo in improving functional status over a long-term
(6 months) follow-up (WMD -4.93; 95% CI -10.11 to
0.25) (Table 2, Analysis 01.02).
In patients unresponsive to treatment with IDET, one
high RoB RCT found radiofrequency denervation of the
ramus communicans nerve was associated with better VAS
pain, SF-36 bodily pain and SF-36 physical function scores
after 4 months compared to sham denervation [30]. In one
RCT, four patients who underwent IDET experienced
transient radiculopathy (\6 weeks) [27]. No other serious
adverse events were reported in the three trials.
Zygapophyseal joint (facet joint)
Radiofrequency denervation of facet joints versus placebo:
pain Five RCTs provided sufﬁcient data on pain VAS
scores to allow for pooling over a short-, intermediate- or
long-term follow-up [31, 33–36]. All studies included only
patients with a positive response (*50–80% pain relief) to
local anaesthetic nerve block. One RCT was not included
in the primary analyses due to clinical heterogeneity of
patient selection procedures [32].
For short-term outcomes (\4 weeks), the Chi-square
value for homogeneity of the WMD was 1.07 (P[0.05),
indicating statistical homogeneity between two of the
RCTs. There is low quality evidence (2 RCTs; n = 90;
indirectness, imprecision) that radiofrequency denervation
of lumbar facet joints is more effective than placebo for
pain relief over a short-term follow-up (WMD -18.15;
95% CI -24.21 to -12.09) (Table 2, Analysis 02.01).
For intermediate-term outcomes (1–6 months), the Chi-
square value for homogeneity of the WMD was 1.75
(P[0.05). There is low quality evidence (2 RCTs;
n = 112; indirectness, imprecision) that radiofrequency
denervation of lumbar facet joints is no more effective than
placebo for pain relief in the intermediate term (WMD
-9.29; 95% CI -22.57 to 4.00) (Table 2, Analysis 02.02).
For long-term outcomes (6 months), the Chi-square
value for homogeneity of the WMD was 4.58 (P[0.05).
There is low quality evidence (3 RCTs; n = 130; indi-
rectness, imprecision) that radiofrequency denervation of
lumbar facet joints is no more effective than placebo for
pain relief in the long term (WMD -6.99; 95% CI -14.73
to 0.76) (Table 2, Analysis 02.03).
When the study by Leclaire and colleagues [32]w a s
included in the analyses, the pooled WMD (95% CI) for pain
intensity was -14.80 (-22.77 to -6.82) in the short-term
and -3.85 (-16.27 to 8.57) in the intermediate term. While
the addition of thisstudy tothe meta-analyses slightly altered
the pooled WMD, it did not change the conclusions.
One RCT with low RoB [37] compared radiofrequency
denervation of the dorsal root ganglion with sham dener-
vation. No signiﬁcant differences were found between
groups at 3-month follow-up. Adverse events and compli-
cations did not differ between treatments, and no serious
complications or side effects arose in either group. There is
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indirectness, imprecision) that radiofrequency denervation
of the dorsal root ganglion is no more effective than pla-
cebo for pain relief in the intermediate term.
Radiofrequency denervation of facet joints versus placebo:
functional status One RCT comparing conventional and
pulsed radiofrequency denervation to placebo provided
sufﬁcient data on functional status outcomes (ODI 0–100
scale) to allow for statistical pooling [34].
There is very low quality evidence (1 RCT; n = 60;
inconsistency, indirectness, imprecision) that radiofrequency
denervation of lumbar facet joints is more effective than
placeboforimprovementoffunctionintheshortterm(WMD
-5.53; 95% CI -8.66 to -2.40) (Table 2,A n a l y s i s0 2 . 0 4 ) .
When the study by Leclaire and colleagues [32] was
included in the analyses, the WMD (95% CI) became
-3.45 (-7.68 to 0.77) in the short term and -6.57 (-17.00
to 3.85) in the intermediate term (when pooled with the
study by van Kleef et al. [35]). While the addition of this
study to the meta-analyses slightly altered the short-term
pooled WMD, it also changed the GRADE proﬁle and the
overall quality of the evidence from very low to low.
Radiofrequency denervation of facet joints versus other
treatment In a study with low RoB [34], conventional
radiofrequency denervation of the lumbar facet joints was
compared with pulsed radiofrequency denervation. Both
treatments improved pain VAS and ODI scores compared
with placebo, with conventional denervation improving
signiﬁcantly more than pulsed denervation by 6 months
and 1 year post-treatment.
There is very low quality evidence (1 RCT; n = 40;
inconsistency, indirectness, imprecision) that conventional
radiofrequency denervation is more effective than pulsed
radiofrequency denervation of the facet joints for pain
relief or improvement of function over the long term.
Discussion
In this review, 27 RCTs were included that evaluated the
effectiveness of injection therapy and denervation proce-
dures for chronic LBP.
The effectiveness of the different therapies
In this review we found only low to very low quality
evidence to support the use of injection therapy and
denervation procedures in chronic LBP patients. Low
quality evidence means that further research is very likely
to have an important impact on our conﬁdence in the
estimate of effect and is likely to change the estimate.
From the 26 included RCTs, only two treatment sub-
groups (IDET vs. placebo, and radiofrequency denervation
of facet joints vs. placebo) were considered to be clinically
homogeneous enough to allow for statistical pooling. The
results showed that IDET is more effective than placebo for
pain relief over 6 months of follow-up and radiofrequency
denervation of lumbar facet joints more effective than
placebo for pain relief over a short-term (\4 weeks) fol-
low-up. The quality of the evidence in both of these
comparisons was downgraded to low quality due to
imprecision and indirectness. Indirectness (lack of ability
to generalize) refers to the extent to which the people,
interventions and outcomes in the trials are not comparable
to those deﬁned in the inclusion criteria of the review. As
all of the pooled RCTs selected patients for inclusion only
if they had a positive response to either provocative dis-
cography (IDET vs. placebo) or local anesthetic nerve
block (radiofrequency denervation of facet joints vs. pla-
cebo). While the selection of appropriate patients may be
considered necessary for these therapies, the results cannot
be generalized to all patients with chronic LBP. However,
from the perspective of pain clinics or anesthesiologists
these populations may be generalizable to their setting. In
that case, the level of evidence is moderate, indicating that
further research is likely to have an important impact on
our conﬁdence in the estimate of effect and may change the
estimate. Consequently, further research is needed for a
more conﬁdent estimate of effect.
Methodological considerations
The RoB assessment describes whether a RCT reported
certain methodological features known to decrease bias
when interpreting the results. However, despite the fact that
the RoB of the included studies was generally low, many
studies showed ﬂaws regarding concealment of treatment
allocation, care provider blinding, avoidance of co-inter-
ventions and performing intention-to-treat analyses. Over-
all, only low to very low quality evidence was found by
this review. By using the GRADE approach, we were able
to determine an overall judgment of the quality of the
evidence not only from the limitations in design, but also
considering aspects such as inconsistency among studies,
imprecision and indirectness.
It is recommended that study features which are asso-
ciated with a lower RoB in RCTs be considered when
designing future trials of non-surgical interventional ther-
apy, as well as adequate reporting of these features.
Adverse effects
In the majority of studies presented in this review, no
adverse events or side effects associated with the
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increased low-back discomfort or paraesthesia were noted
in a few studies. Epidural injections were associated with
nausea and headache in some patients. In a study which
used discectomy as a reference treatment [11], a dural
defect with leakage of cerebrospinal ﬂuid and a partial
cauda equina were noted, though unsure whether these
patients were in the injection therapy or surgery group.
Most trials were small and not designed to evaluate adverse
events, so no clear conclusion can be drawn regarding the
risks of injection therapy and denervation procedures.
Strengths and limitations
Several biases can be introduced in systematic reviews by
literature search and selection procedures. It is possible that
in searching studies for this review, relevant but unpub-
lished trials may have been missed, which are often likely
to be small studies without positive results, leading to
publication bias. However, because the majority of pub-
lished trials was small and did not show a positive effect,
publication bias does not seem to be a big problem in this
review. Screening references of identiﬁed trials and sys-
tematic reviews may result in an over representation of
positive studies in the review, because trials with a positive
result are more likely to be referred to in other publications,
leading to reference bias. Only studies published in Eng-
lish, Dutch, French or German were included in this
review. It is not clear whether a language restriction is
associated with bias [38].
Due to the study selection criterion used, including only
trials of chronic ([3 months duration) LBP patients, this
review included less studies than similar Cochrane reviews
[3, 5]. Many excluded RCTs failed to explicitly state the
duration of symptoms experienced by the patients, while
others considered only the length of time patients were
unresponsive to conservative treatment as part of their
inclusion criteria. However, the main conclusions of our
review appear to be similar to recent systematic reviews
[3–6], which generally report a paucity of RCTs on
injection therapy and denervation procedures for chronic
LBP and insufﬁcient evidence to support their use.
Implications for research
To conclude, we identiﬁed 27 RCTs that evaluated various
types of injection therapy or denervation procedures at
different locations for patients with chronic LBP. Most of
the studies included in this review were small and had a
low RoB, though there were methodological weaknesses,
especially regarding concealment of allocation, co-inter-
ventions and use of intention-to-treat analyses. The quality
of evidence was low or very low, indicating that further
research is very likely to have an important impact on our
conﬁdence in the estimate of effect and is likely to change
the estimate. There is a need for future high-quality pla-
cebo-controlled RCTs with large sample sizes on injection
therapy and denervation procedures.
Implications for practice
In patients with chronic LBP there is only low to very low
quality evidence to support the use of injection therapy for
pain relief and improvement of function. It cannot be ruled
out that in carefully selected sub-groups of patients, such as
those with a positive response to discography or local
anaesthetic nerve block, certain interventional therapies
may be of some beneﬁt. Potential beneﬁts must be weighed
against possible adverse effects when deciding whether to
provide injection therapy or denervation to chronic LBP
patients.
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See Table 3.
Table 3 Characteristics of included studies
Study: Barendse 2001
Methods RCT; ‘‘randomized to two treatment groups by computer program’’
Participants 28 patients, aged 30–65 years, with a history of chronic LBP[12 months referred to a pain management centre. Only patients
with a positive response to analgesic discography ([50% temporary reduction in pain over 30 min) were included. Exclusion
criteria were multilevel discogenic pain, spinal stenosis, spondylolisthesis, coagulation disturbances, pregnancy, high VAS,
diabetes mellitus, and positive diagnostic block of L3, L4 or L5 zygapophysial joints
Interventions Injection treatment (I): percutaneous intra-discal radiofrequency thermocoagulation (radiofrequency probe inserted via cannula
into disc using tunnel vision ﬂuoroscopy), creating a 90-s 70C lesion (n = 13)
Reference treatment (R): sham radiofrequency thermocoagulation (treated in an identical way, but no radiofrequency current
was applied) (n = 15)
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Outcomes No signiﬁcant differences were found for any of the primary or secondary outcomes after 8 weeks post-treatment. Change in
VAS was -0.61 in (I) and -1.14 in (R); while change in Oswestry scale was -2.62 in (I) and -4.93 in (R)
Notes No complications during or after the procedures were reported.
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded ?; outcomes blinded ?; co-interventions ?; compliance ?; drop outs -; timing of outcomes ?; intention-to-treat ?.
Total score = 9
Study: Carette 1991
Methods RCT; ‘‘generated from a table of random numbers’’
Participants 101 patients, aged 18–65 years, with chronic LBP and a positive response to lumbar facet joint anaesthetic block. Exclusion
criteria included speciﬁc LBP, previous injections into the facet joints, previous low-back surgery, pregnancy, known allergy
to local anaesthetic and the presence of a blood coagulation disorder
Four patients were later excluded from the analysis.
Interventions Injection treatment (I): lumbar facet joint injection of corticosteroid (1 ml methylprednisolone acetate mixed with 1 ml isotonic
saline) (n = 49)
Reference treatment (R): sham lumbar facet joint injection (2 ml isotonic saline) (n = 48)
Outcomes One to 3 months post-treatment, the two groups did not differ clinically or statistically in any of the outcome measures. By
6 months post-treatment, patients treated with (I) reported signiﬁcantly better VAS (mean difference -1.0, 95% CI -2.0 to -
0.1) and sickness impact proﬁle-physical dimension scores (mean difference -3.0, 95% CI -5.5 to -0.5) compared with (R)
Notes No adverse events were reported, other than transient local pain at the injection sites.
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded ?; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat -.
Total score = 8
Study: Dashﬁeld 2005
Methods RCT; ‘‘allocated randomly’’
Participants 60 patients, aged 18 years or more, with sciatica (deﬁned as pain in the distribution of a lumbar nerve root, ± neurosensory and
motor deﬁcits) for a minimum of 6 months, but not for longer than 18 months. Patients with previous spinal surgery,
coagulopathy, progressive motor neurone disorders, or peripheral vascular disease were excluded
Interventions Injection treatment (I): caudal epidural corticosteroid injection (10 ml lidocaine 1% with 40 mg triamcinolone) injected into the
epidural space (n = 33)
Injection treatment (I2): lumbar epiduroscopy (painful nerve root identiﬁed and instilled with 10 ml lidocaine 1% with
triamcinolone 40 mg) (n = 27)
Outcomes No signiﬁcant differences were found between the groups after 6 weeks, 3 months and 6 months post-treatment for any of the
measures. For the (I) group, there were more signiﬁcant differences between pre-treatment and post-treatment outcome
measures compared with the (I2) group
Notes Non-persistent post-procedure low-back discomfort occurred in all (I2) patients, and in fewer (I) patients
Methodological quality: randomization ?; treatment allocation ?; baseline similarity -; patients blinded ?; care providers
blinded -; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 6
Study: Ercelen 2003
Methods RCT; ‘‘patients were randomized into two treatment groups by computer’’
Participants 39 patients with chronic LBP who had been receiving conservative treatment for at least 2 years. Patients with spinal stenosis,
instability, spondylolisthesis, diabetes mellitus, tumour inﬁltration, coagulation disorders, clinical radiculopathy, other
neurologic abnormalities or systemic inﬂammatory diseases were excluded from the study. Only patients with a positive
provocative discography at L4–L5, L5–S1, or both locations were randomized
Two patients were excluded from the analysis (one with discitis, one lost to follow up)
Interventions Injection treatment (I1): percutaneous intradiscal radiofrequency thermocoagulation (radiofrequency probe inserted via cannula
into disc using ﬂuoroscopy) at 80C. Lesioning was performed for 120 s (n = 19)
Injection treatment (I2): percutaneous intradiscal radiofrequency thermocoagulation, identical procedure to (I1) but lesioning
was performed at 80C for 360 s (n = 18)
Outcomes No signiﬁcant differences were observed between groups at any of the follow-up time points (post-treatment, 1 and 2 weeks, 1,
3, and 6 months). Post-treatment to 1 month scores on pain VAS and Oswestry disability scale decreased signiﬁcantly
compared with pre-treatment scores (P\0.05). There were no statistical differences between the ﬁnal (6 month) and the pre-
treatment VAS and ODS values in both groups
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Notes Adverse events were not reported
Methodological quality: randomization ?; treatment allocation -; baseline similarity ?; patients blinded ?; care providers
blinded -; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 4
Study: Foster 2001
Methods RCT; ‘‘randomly assigned by drawing a card from a deck of shufﬂed cards’’
Participants 31 patients aged[18 years with chronic LBP greater on one side than the other. Exclusion criteria were LBP for\6 months,
presence of a systemic inﬂammatory disorder, acute pathology on MRI, known allergy or sensitivity to botulinum toxin,
pregnancy, disorders of neuromuscular transmission and anaesthetic or corticosteroid injections to the lumbar spine within
12 weeks of enrolment
Interventions Injection treatment (I): intramuscular injections of botulinum toxin A at 5 lumbosacral sites, with each site receiving 40 units
(n = 15)
Reference treatment (R): intramuscular injections of saline to at 5 lumbosacral sites, with each site receiving 40 units (n = 16)
Outcomes At 3 weeks, the degree of pain relief exceeded 50% (VAS score) in 11 of 15 patients (73.3%) in the (I) group compared with
four of 16 (25%) in the (R) group (P\0.012). The difference between these groups was 48% (95% CI 11.7–80.1). At
8 weeks, 9 of 15 patients (60%) in the (I) group and 2 of 16 (12.5%) in the (R) group reported pain relief exceeding 50%
(P\0.009), a difference of 47.5% (95% CI 10.5–79.1). For the Oswestry, 10 of 15 patients (66.7%) in the (I) group and 3 of
14 (18.8%) in the (R) group demonstrated improvement at 8 weeks (P\0.011). The difference between groups was 47.9%
(95% CI 10.9–79.6)
Notes Injections were well tolerated by all patients and none had side effects
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded -; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 9
Study: Freeman 2005
Methods RCT; ‘‘randomization schedule’’
Participants 57 patients with chronic LBP and evidence of degenerative disc disease on MRI. All subjects had one- or two-level symptomatic
disc degeneration as determined by provocative lumbar discography. Exclusion criteria included the presence of a large
contained or sequestered herniation, spinal stenosis, previous back surgery, spondylolisthesis, psychological disorders, and
pregnancy
Two subjects violated protocol and were not included in the analysis
Interventions Injection treatment (I): intradiscal electrothermal therapy (IDET) at 90C for 4 min, followed by a rehabilitation program
(n = 38)
Reference treatment (R): sham IDET, same procedure as (I) without connection to the generator, followed by a rehabilitation
program (n = 19)
Outcomes 6 months post-treatment, there were no signiﬁcant differences between groups on any of the primary or secondary outcome
measures. Mean difference (95% CI) between groups on the low-back outcome score was -1.71 (-3.82 to 0.41) and on
Oswestry was -2.16 (-8.37 to 4.86) in favour of (I)
Notes There were no serious adverse events in either arm of the study
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded ?; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat -.
Total score = 8
Study: Fuchs 2005
Methods RCT; block randomization generated by computer
Participants 60 patients with chronic LBP with radiologic conﬁrmation of facet joint osteoarthritis. Patients with a history of hypersensitivity
or contraindication to the test products, contraindication to intra-articular treatment, a current regimen of anticoagulants or
radicular pain were excluded from the study
Interventions Injection treatment (I): lumbar facet joint sodium hyaluronate injections (10 mg sodium hyaluronate in 1 ml buffer solution)
bilaterally, under CT guidance at weekly intervals, for 3 weeks (n = 30)
Injection treatment (I2): lumbar facet joint corticosteroid injection (10 mg triamcinolone acetonide in 1 ml crystalline
suspension) bilaterally, under CT guidance at weekly intervals, for 3 weeks (n = 30)
Outcomes No statistically signiﬁcant differences between the groups in any outcomes were reported post-treatment, after 3 and 6 months.
Pain VAS in the (I) group decreased from 69.2 ± 14.2 to 38.0 ± 26.5 mm by 3 months post-treatment. In the (I2) group the
pain intensity decreased from 68.7 ± 11.5 to 33.4 ± 20.7 mm
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Notes No adverse effects were reported after administration of both therapies
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded -; care providers
blinded -; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat -.
Total score = 5
Study: Gallagher 1994
Methods RCT; randomisation method not stated
Participants 41 patients, aged 25–55 years, with chronic LBP who fulﬁlled criteria for facet joint pain (including tenderness on palpation;
pain on extension or rotation; pain exacerbated by exercise, sitting, and standing; and radiological evidence of facet joint
degeneration). Subjects had a positive response to local anaesthetic injection into and around the painful joint. Exclusion
criteria included previous back surgery, signs of nerve root compression, major mental illness, pending compensation claims
and general ill health
Interventions Injection treatment (I): radiofrequency denervation of lumbar facet joints at 80C for 90 s (n = 24)
Reference treatment (R): sham radiofrequency denervation with identical procedure except for the radiofrequency lesion
(n = 27)
Outcomes Analyses were split to allow comparisons between those with a good (n = 30) or equivocal (n = 11) response to facet joint
block. Subjects with a good response in the (I) group had signiﬁcantly lower mean (SE) VAS (34 (6.9) vs. 60 (9.8)) and McGill
pain scores (9 (2.3) vs. 16 (2.8)) 1 month post-treatment, compared with the (R) group. 6 months post-treatment VAS scores
were signiﬁcantly low in the (I) compared with (R). In subjects with an equivocal response to facet joint block, no signiﬁcant
differences were found between groups at any time-point
Notes Adverse events were not reported
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded -; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 6
Study: Geurts 2003
Methods RCT; ‘‘randomly allocated’’
Participants 83 patients, aged 18 years and more, with chronic LBP and a predominance of leg pain who responded positively to lumbar
nerve blocks. Exclusion criteria were: previous radiofrequency treatment; indications for surgery (great pain, rapid progressive
paresis, cauda equina syndrome); pregnancy; coagulation disorders; malignant disease; allergy to radiopaque contrast or local
anaesthetics; and presence of neuropathic sensory or motor deﬁcit, a non-segmental pattern of irradiating leg pain, or both
Three patients required surgery post-treatment and were excluded from the analysis
Interventions Injection treatment (I): radiofrequency lesioning of dorsal root ganglion at 67C for 90 s (n = 44)
Reference treatment (R): sham radiofrequency lesioning of dorsal root ganglion, identical procedure as (I) without the
application of radiofrequency current (n = 36)
Outcomes Three months post-treatment, 16% of (I) were assessed to have had successful treatment compared with 25% in (R) group, based
on a composite outcome measure (difference -9.1% [95% CI -33.0 to 12.0], P = 0.43). No signiﬁcant differences between
groups were reported for mean change scores (SD) on back pain VAS (I) -0.6 (2.2) versus (R) -1.1 (2.4); change in daily
activities (I) -0.5 (3.9) versus (R) -0.4 (3.4); change in analgesics use (I) 0.1 (1.4) versus (R) -0.2 (0.9); global subjective
efﬁcacy rating of beneﬁt (I) 21% versus (R) 17%; or on any SF-36 subscales
Notes 41 patients had at least one previous low-back surgery
Adverse events did not differ between treatments, and no serious complications or side effects arose in either group
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded ?; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 10
Study: Kvarstein 2009
Methods RCT; ‘‘randomized’’
Participants 20 patients aged 20–65 years, with unremitting low-back pain for 6 months. All patients with signs of disc degeneration (MRI)
or posterior annular tear (CT) underwent a three-level (L3/L4, L4/L5 and L5/S1) pressure-controlled provocation discography.
Patients were eligible if the discography reproduced typical (‘‘concordant’’) and intensive low-back pain ([7/10) at only one of
the three levels. All eligible patients had pain[5/10 which was exacerbated by sitting and relieved by laying. Exclusion
criteria included: positive medial branch blocks, acute infection, history of drug abuse, psychological disturbance, previous
spine surgery, abnormal neurological examination, structural deformities or canal stenosis, pregnancy and disc herniations
[4m m
Interventions Injection treatment (I): percutaneous intradiscal radiofrequency thermocoagulation (PIRFT) at a single level for 10 min (starting
at 50C, increasing by 5C every 2 min, and ending with 4 min at 65C) (n = 10)
Reference treatment (R): sham percutaneous intradiscal radiofrequency thermocoagulation (PIRFT), same procedure as above
but the annulus was not exposed to RF heating (n = 10)
1438 Eur Spine J (2010) 19:1425–1449
123Table 3 continued
Outcomes After 6 months, there were no signiﬁcant differences between (I) and (R) on pain intensity. Mean (SD) pain intensity at baseline,
6 and 12 months: (I) 5.4 (2.1), 4.4 (2.7), 4.0 (3.0) versus (R) 6.5 (2.2), 6.5 (2.0), 4.9 (2.7), respectively. No signiﬁcant
differences were observed between groups on any of the secondary outcome measures
Notes Any serious adverse effects attributable to the treatment were not reported
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded -; outcomes blinded ?; co-interventions -; compliance -; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 8
Study: Leclaire 2001
Methods RCT; ‘‘randomization was performed in blocks of four’’
Participants 70 patients, aged 18–65 years, with chronic LBP and positive lumbar facet joint block. Exclusion criteria included allergy to
local anaesthetic, blood coagulation disorder, cardiac pacemaker, sciatic pain with neurological deﬁcit, speciﬁc low-back pain
and previous low-back surgery
Interventions Injection treatment (I): radiofrequency facet joint denervation under ﬂuoroscopic guidance, 80C for 90 s at a minimum of two
levels (n = 36)
Reference treatment (R): sham radiofrequency denervation, same procedure as (I), without radiofrequency lesion (n = 34)
Outcomes After 4 weeks, mean (SD) Roland–Morris scores improved by 8.4 (17.4) in the (I) group and by 2.2 (14.7) in (R), showing a
mean difference (95% CI) of 6.2 (-1.3 to 13.8). There was no signiﬁcant treatment effect after 12 weeks. No signiﬁcant
differences were found at any time point for pain VAS, Oswestry score, or the secondary outcomes
Notes No complications after the intervention was reported by patients
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded -; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 10
Study: Lierz 2004
Methods RCT; randomization performed by computer
Participants 40 patients, aged 20–70 years, with chronic LBP. Exclusion criteria included presence of a motor deﬁcit, recent change of
analgesics, pulmonary hypertension, pulmonary artery stenosis, aortic stenosis, mitral stenosis, AV-block grade III, extreme
hypovolaemia, coagulation disorders, pregnancy or sepsis/infection
Interventions Injection treatment (I): lumbar epidural block (10 ml ropivacaine 0.2%) (n = 20)
Injection treatment (I2): lumbar epidural block (10 ml bupivacaine 1.125%) (n = 20)
Eight single shot epidural blocks at an interval of 2 or 3 days. Active physiotherapy was performed immediately after each
session in both groups
Outcomes There was no signiﬁcant difference between groups in analgesia post-treatment. Mean (SD) pain intensity in (I) decreased from
7.0 (1.6) to 4.0 and from 7.1 (1.6) in (I2) to 4.2. No signiﬁcant differences between groups were reported in haemodynamic
variables
Notes There were three cases of short episodes of headache, two in the (I) group and one in the (I2) group.
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded ?; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat -.
Total score = 8
Study: Lilius 1989
Methods RCT; randomisation method not stated
Participants 109 patients aged 19–64 years with chronic LBP
Interventions Injection treatment (I): lumbar facet joint injection of corticosteroid and local anaesthetic [6 ml (30 mg) bupivacaine
hydrochloride mixed with 2 ml (80 mg) methylprednisolone acetate] (n = 28)
Injection treatment (I2): the same mixture, injected peri-capsularly around the lumbar facet joint (n = 39)
Reference treatment (R): sham lumbar facet joint injection (8 ml of physiological saline) (n = 42)
Outcomes No signiﬁcant differences between groups was seen post-treatment, after 2 weeks, or after 6 weeks in work status, pain intensity,
or physical range of motion measurements. Data in graphs
Notes Twenty-seven patients had a history of previous vertebral disc surgery
Few side effects were reported and their occurrence did not differ between groups
Methodological quality: randomization ?; treatment allocation -; baseline similarity ?; patients blinded -; care providers
blinded -; outcomes blinded -; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat -.
Total score = 3
Study: Manchikanti 2001
Methods RCT; randomization procedure not described
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Participants 73 patients with LBP with or without lower extremity pain for more than 6 months who did not exhibit neurological deﬁcits and
who responded positively to lidocaine blocks
Interventions Injection treatment (I): lumbar facet joint injection with local anaesthetic and Sarapin (0.5% lidocaine or 0.25% bupivacaine
mixed with equal volumes of Sarapin) (n = 32)
Injection treatment (I2): lumbar facet joint injection with a mixture of local anaesthetic, Sarapin, and corticosteroid (0.5%
lidocaine or 0.25% bupivacaine mixed with equal volumes of Sarapin and 1 mg of methyl prednisolone/ml of the mixture)
(n = 41)
Outcomes Results showed that patients underwent multiple procedures over a period of 2 years. Post-treatment, no signiﬁcant differences
were reported between the groups in pain relief, overall health status, physical, functional or psychological status. Average
pain scores (mean ± SEM) decreased from 7.6 ± 0.13 to 3.5 ± 0.26 in (I) and from 7.7 ± 0.12 to 3.3 ± 0.15 in (I2)
Notes 17 patients had previous lumbar laminectomy
No complications were reported in any of the patients
Methodological quality: randomization ?; treatment allocation -; baseline similarity ?; patients blinded -; care providers
blinded -; outcomes blinded ?; co-interventions -; compliance ?; drop outs ?; timing of outcomes -; intention-to-treat -.
Total score = 3
Study: Manchikanti 2008
Methods RCT; ‘‘computer-generated random allocation sequence’’
Participants 120 patients aged over 18 years with chronic non-speciﬁc LBP and a diagnosis of lumbar facet joint pain by lumbar anaesthetic
block. Exclusion criteria were lack of positive response to controlled comparative local anaesthetic blocks, uncontrollable or
unstable opioid use, psychiatric disorders, pregnancy, and patients with a history or potential for adverse reaction(s) to local
anaesthetic, Sarapin or steroid
Interventions Injection treatment (I): lumbar facet joint nerve blocks with local anaesthetic (bupivacaine 0.25%) (n = 60)
Injection treatment (I2): lumbar facet joint nerve blocks with a mixture of bupivacaine and betamethasone (n = 60)
Outcomes There were no signiﬁcant differences in treatment effect of (I) compared to (I2) at 3, 6, or 12 months post-treatment. Pain scores
(mean ± SD) at baseline: (I) 8.2 ± 0.8, (I2) 7.9 ± 1.0; at 3 months (I) 3.8 ± 1.3, (I2) 3.5 ± 1.1; at 6 months (I) 3.6 ± 1.5,
(I2) 3.3 ± 0.8; and at 12 months (I) 3.7 ± 1.7, (I2) 3.5 ± 1.1
Notes There were no major adverse events reported over a period of 1 year
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded -; outcomes blinded ?; co-interventions -; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 8
Study: Marks 1992
Methods RCT; ‘‘random number system’’
Participants 86 patients with chronic LBP present most of the time for at least 6 months. Exclusion criteria were a radicular pattern in either
lower limb, straight leg raising limited at\60, and evidence of any progressive spinal disorder of non-degenerative origin
Interventions Injection treatment (I): lumbar facet joint injection with corticosteroids and anaesthetic (20 mg methylprednisolone acetate
followed by 1.5 ml lignocaine) (n = 42)
Injection treatment (I2): lumbar facet nerve block of the medial articular branch of the posterior primary ramus from L1 to L5
(20 mg methylprednisolone acetate followed by 1.5 ml lignocaine) (n = 44)
Outcomes (I) was slightly better in relieving pain than (I2). This difference reached statistical signiﬁcance only at 1 month (P\0.005) but
not immediately after treatment, at 2 weeks, or at 3 months. 1 month post-treatment, 65.9% (n = 29) of (I2) reported no
change in pain severity compared to 42.9% (n = 18) in (I)
Notes 5 subjects in each group had previous lumbar spine surgery
No serious complications were reported. Transient symptoms, such as headache, paraesthesia of one leg, nausea and worsening
of pain occurred 15 times in (I) and 18 times in (I2)
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded ?; outcomes blinded ?; co-interventions -; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat -.
Total score = 8
Study: Mauro 2000
Methods RCT; randomization procedure not described
Participants 60 patients, aged 18–65 years, with chronic LBP or sciatic neuritis of mechanical origin for at least 6 months, and a pain
intensity of at least 60 mm on a VAS. Exclusion criteria included pregnancy, severe concurrent illnesses, and intolerance to
paracetamol
Interventions Injection treatment (I): intramuscular injection (2 ml ampoules containing 1,000 mg vitamin B12) once daily for a 2-week
period (n = 30)
Reference treatment (R): sham intramuscular injection (2 ml placebo ampoules) once daily for a 2-week period (n = 30)
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Outcomes At the end of the treatment period, pain VAS scores (mean ± SD) signiﬁcantly decreased in (I) (75.53 ± 8.9 to 9.53 ± 16.5)
compared with (R) (70.63 ± 7.9 to 36.83 ± 27.4) (P\0.0001). Total scores on RDQ (mean ± SD) signiﬁcantly declined
more in (I) (from 13.27 ± 2.7 to 2.43 ± 2.6) than in (R) (from 11.53 ± 2.2 to 5.80 ± 3.3) (P\0.0002). Mean consumption
of paracetamol over the treatment period was higher in (R) compared to (I) (P\0.01)
Notes No changes in vital signs or adverse effects were noted
Methodological quality: randomization ?; treatment allocation ?; baseline similarity -; patients blinded ?; care providers blinded
?; outcomes blinded ?; co-interventions ?; compliance ?; drop outs -; timing of outcomes ?; intention-to-treat -. Total
score = 3
Study: Mayer 2004
Methods RCT; assignment based on date of the month of their initial visit
Participants 70 patients with chronic disabling work-related lumbar spine disorders who had lumbar rigidity between 1 and 3 levels.
Exclusion criteria included failure to achieve insurance pre-authorization and more than three levels of spinal rigidity
Interventions Injection treatment (I): lumbar facet joint injection on one to three levels bilaterally (1 ml 2% lidocaine, 1 ml 0.5% bupivacaine,
and 1 ml of a depot corticosteroid preparation). In addition, a home stretching exercise program was instructed (n = 36)
Reference treatment (R): home stretching exercise program (n = 34)
Outcomes No signiﬁcant differences were found in pain and disability between the groups. The (I) group had a signiﬁcantly greater
improvement in range of motion at 5–7 weeks compared withh (R). Pain intensity (mean ± SD) improved from 6.3 ± 1.5 to
5.4 ± 1.6 in (I) and 6.7 ± 1.8 to 5.9 ± 2.1 in (R)
Notes 18 patients had a history of lumbar spinal surgery
Adverse events were not reported by the study authors
Methodological quality: randomization -; treatment allocation -; baseline similarity ?; patients blinded -; care providers
blinded -; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 3
Study: Nath 2008
Methods RCT; ‘‘computer generated randomization schedule’’
Participants 40 patients with chronic LBP of at least 2 years duration with 80% pain relief from two successive medial branch blocks.
Excluded were patients with pregnancy, coagulopathies, malignancy, infections, mental handicap and psychiatric disorders;
patients with a motor deﬁcit or any other indication for surgical treatment
Interventions Injection treatment (I): radiofrequency denervation of lumbar facet joint for 60 s at 85C( n = 20)
Reference treatment (R): sham radiofrequency denervation of lumbar facet joint, same procedure as (I) but without application
of current (n = 20)
Outcomes At baseline, (I) had signiﬁcantly more generalised pain, low-back pain, hip ROM, and referred pain when compared with (R).
6 months post-treatment, on a 6-point global assessment scale, the (I) group had signiﬁcantly more than the (R) group by 0.8
points (P\0.004). Mean low-back pain VAS improved from 6.03 to 4.10 in (I) and from 4.35 to 3.98 in (R) (P = 0.02). In
various secondary outcome measures, the (I) group exhibited improvements that were statistically and clinically greater than
those in the (R) group
Notes Adverse events were not reported
Methodological quality: randomization ?; treatment allocation ?; baseline similarity -; patients blinded ?; care providers
blinded ?; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 6
Study: Oh 2004
Methods RCT; ‘‘randomly allocated’’
Participants 49 patients with chronic discogenic LBP whose pain continued after undergoing intradiscal electrothermal annuloplasty (IDET)
and who also had a positive diagnostic block of the ramus communicans nerve. Exclusion criteria were: spinal stenosis, spinal
instability, multilevel (2 or more) disc lesions, previous spinal surgery, history of excessive bleeding or coagulopathy and
obvious psychologic problems. Patients with a positive diagnostic block of the facet joints were also excluded
Interventions Injection treatment (I): radiofrequency thermocoagulation of the ramus communicans nerve (1% lidocaine was injected followed
by RF thermocoagulation) at 65C for 60 s (n = 26)
Reference treatment (R): sham radiofrequency thermocoagulation, same procedure as (I), injection of 2 ml of preservative-free
1% lidocaine without RF thermocoagulation (n = 23)
Outcomes After 4 months, VAS pain scores were signiﬁcantly lower in the (I) group than in the (R) group (P\0.05). The scores of the (I)
group were a mean of 11.3 points higher (P\0.05) on the bodily pain subscale, and a mean of 12.4 points higher (P\0.05)
on the SF-36 physical function subscale, compared with the (R) group
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Notes One patient in the (I) group complained of mild lower limb dysesthesia and weakness
Methodological quality: randomization ?; treatment allocation -; baseline similarity ?; patients blinded ?; care providers
blinded -; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 3
Study: Pauza 2001
Methods RCT; ‘‘computer-generated, random numbers’’
Participants 64 patients aged 18–65 years with chronic LBP greater than leg pain and a posterior tear of the annulus ﬁbrosus on provocation
discography. Exclusion criteria were previous lumbar spine surgery; abnormal neurological examination; radicular pain;
structural deformities; large or sequestered disc herniations; cervical or thoracic pain; uncontrolled or acute medical illnesses;
rheumatoid arthritis; ambulatory dysfunction; pregnancy; workman’s compensation; injury litigation; disability remuneration;
and allergy to contrast media or drugs to be used in the intended procedure
Eight patients violated the protocol and were excluded from the ﬁnal analysis
Interventions Injection treatment (I): intradiscal electrothermal therapy (IDET) to 90C and a 12-week post-operative rehabilitation program
(lumbar corset for 6 weeks, spine stabilization exercises for 6 weeks) (n = 32)
Reference treatment (R): sham intradiscal electrothermal therapy, same procedure as above without application of current, and a
12-week post-operative rehabilitation program (n = 24)
Outcomes 6 months post-treatment, pain VAS scores (mean ± SD) in the (I) group decreased signiﬁcantly more (6.6 ± 1.4 to 4.2 ± 2.6)
than the (R) group (6.5 ± 1.9 to 5.4 ± 2.7) (P\0.05). Oswestry disability scores (mean ± SD) decreased from 31 ± 10 to
20 ± 12 in (I) and from 33 ± 11 to 28 ± 15 in (R) (P = 0.05)
Notes No patient had any adverse effects attributable to their treatment
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded -; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat -.
Total score = 9
Study: Revel 1998
Methods RCT; randomisation method not stated
Participants 80 patients aged 18 years or more with chronic LBP unrelieved by analgesics, NSAIDs, and physical therapy. Exclusion criteria
included previous back surgery, sciatica, sacroiliac joint pain, pregnancy, psychiatric disease and a history of adverse reaction
to a lidocaine or corticosteroid injection
Interventions Injection treatment (I): lumbar facet joint injection with anaesthetic (1 ml 2% lidocaine) (n = 42)
Reference treatment (R): lumbar facet joint injection with 1 ml saline (n = 38)
Patients had 4–6 lower joints injected on both sides or 2–3 on the same side
Outcomes Post-treatment, pain relief was signiﬁcantly better in the (I) group compared with the (R) group. In patients with fewer pain
characteristics, pain (mean ± SD) decreased by -35.36 ± 23.6 in (I) compared to -11.87 ± 17.44 in (R) (P = 0.01)
Notes Adverse events were not reported
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded ?; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 7
Study: Serrao 1992
Methods RCT; ‘‘randomly allocated’’
Participants 28 patients attending chronic LBP treatment. Patients with disc lesions and spinal claudication were excluded
Interventions Injection treatment (I): lumbar epidural injection with corticosteroid (80 mg prednisolone) plus 3 ml 5% dextrose injected into
the intrathecal space (n = 14)
Injection treatment (I2): lumbar epidural injection (10 ml normal saline) plus 2 mg midazolam dissolved in 3 ml 5% dextrose
injected into the intrathecal space (n = 14)
Outcomes There were no signiﬁcant differences between the groups post-treatment, or after 2 months follow-up for either pain intensity or
unpleasantness. No signiﬁcant differences were found between groups on psychological measures. Data in graphs
Notes Eight patients in the (I) group and seven in the (I2) group experienced headaches following treatment; nausea was experienced in
two of the (I) patients and by one patient in the (R) group
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers blinded
?; outcomes blinded ?; co-interventions -; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?. Total
score = 4
Study: Tekin 2007
Methods RCT; ‘‘random number generation’’
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Participants 60 patients, aged[17 years, with chronic LBP with or without radiating pain into the upper leg, focal tenderness over the facet
joints and pain on hyperextension. Exclusion criteria were prior radiofrequency treatment, coagulation disturbances, allergies
to contrast media or local anaesthetics, malignancy, psychiatric conditions and pregnancy. Only patients with a positive
response ([50% pain relief for sufﬁcient duration) to a diagnostic medial branch block were included
Interventions Injection treatment (I): radiofrequency denervation (conventional) medial branch lumbar nerve roots at 80C for 90 s (n = 20)
Injection treatment (I2): radiofrequency denervation (pulsed) medial branch lumbar nerve roots at 42C for 240 s (n = 20)
Reference treatment (R): sham radiofrequency denervation, similar procedure as (I), but only bupivacaine 0.5% 0.3 ml was
injected (n = 20)
Outcomes Post-treatment VAS and ODI scores (mean ± SD) were lower in (I) (2.3 ± 1.4; 25.6 ± 6.5) and (I2) (2.8 ± 1.5; 24.4 ± 5.7)
than in (R) (4.3 ± 1.0; 30.5 ± 5.7) (P\0.001). At 6 months and 1 year follow-up, mean VAS score was similar in (R) and
(I2) groups but lower in the (I) group compared with the others (P\0.05). Mean ODI was lower in (I) and (I2) groups than
(R) group at 1 year (P\0.05)
Patient satisfaction was lower in (R) than other groups (P = 0.03), and highest in (I) (P = 0.004)
Notes There were no complications related to the procedure during the follow-up period
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded -; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 7
Study: van Alphen 1989
Methods RCT; randomization method not stated
Participants 151 patients, aged 18–45 years, with proven disc herniation on myelography. 68 patients had symptoms for[6 months.
Exclusion criteria were severe neurological deﬁcits, previous lumbar disc surgery or chemonucleolysis, and pregnancy
Interventions Injection treatment (I): chemonucleolysis [2 ml (4,000 U) chymopapain injected into intervertebral disc] followed by
physiotherapy (n = 34)
Reference treatment (R): discectomy under general anaesthetic using an interlaminar approach followed by post-operative
physiotherapy (n = 34)
Outcomes 12 months post-treatment, status of pain (disappeared, improved, unchanged, increased) = (I): n = 13, 14, 4, 0; (R): n = 16,
13, 5, 0 (not signiﬁcant)
Notes Complications in both groups included increased neurological symptoms, dural defect with leakage of cerebrospinal ﬂuid, and
partial cauda equina in one patient
Methodological quality: randomization ?; treatment allocation -; baseline similarity ?; patients blinded -; care providers
blinded -; outcomes blinded -; co-interventions ?; compliance -; drop outs -; timing of outcomes ?; intention-to-treat -.
Total score = 2
Study: van Kleef 1999
Methods RCT; ‘‘[randomized] with help of a computer program’’
Participants 31 patients, aged 20–60 years, with chronic LBP for[12 months and a positive diagnostic dorsal ramus nerve block. Patients
with previous back surgery or known speciﬁc LBP were excluded. One patient refused follow-up and was excluded from the
analysis
Interventions Injection treatment (I): radiofrequency denervation of lumbar facet joints (posterior primary ramus of the segmental nerves L3–
L5) at 80C for 60 s on one or both sides (n = 15)
Reference treatment (R): sham radiofrequency denervation, electrodes introduced as in (I) but no radiofrequency current was
applied (n = 16)
Outcomes After 8 weeks, the mean VAS ± SD for (R) and (I) was 4.8 ± 2.5 and 2.8 ± 2.4, respectively. This difference, and the
difference in effect on the Oswestry disability scale and globally perceived effect were statistically signiﬁcant. Three, 6, and
12 months after treatment there were signiﬁcantly more ‘‘success’’ patients in the (I) group compared with (R)
Notes There were no complications during or after the interventions
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded ?; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 7
Study: van Wijk 2005
Methods RCT; randomisation method not stated
Participants 81 patients, aged 17 years and over, with chronic LBP and a 50% pain VAS reduction on lumbar facet joint diagnostic block.
Exclusion criteria were prior radiofrequency treatment, radicular syndrome, coagulopathies, speciﬁc allergies, cancer and
pregnancy
Interventions Injection treatment (I): radiofrequency lumbar facet denervation (dorsal ramus medial branches) at 80C for 60 s (n = 40)
Reference treatment (R): sham radiofrequency denervation, same procedure as (I) but without applying radiofrequency current
(n = 41)
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Outcomes 3 months post-treatment, a combined outcome measure (VAS, physical activities, analgesic intake) showed no differences
between (I) (success 27.5%) and (R) (success 29.3%) (P = 0.86). Globally perceived effect improved after (I) (P\0.05). The
other secondary outcome parameters showed no signiﬁcant differences. Data in graphs
Notes 30% of patients reported treatment-related pain severe enough to necessitate analgesics. No differences were found between
groups on the incidence of adverse events and complications
Methodological quality: randomization ?; treatment allocation ?; baseline similarity ?; patients blinded ?; care providers
blinded ?; outcomes blinded ?; co-interventions ?; compliance ?; drop outs ?; timing of outcomes ?; intention-to-treat ?.
Total score = 10
Table 4 Characteristics of excluded studies
Review Study Reason for exclusion
Staal 2008 Aldrete 2003 Duration of LBP not reported
Beliveau 1971 Duration of LBP not reported
Breivik 1976 Duration of LBP not reported
Collee 1991 Duration of LBP not reported
Garvey 1989 Included patients with duration\3 months
Rocco 1989 All patients had previous laminectomy
Sonne 1985 Included patients with duration\3 months
Takada 2005 Included patients with duration\3 months
Gibson 2007
a Schwetschenau 1976 Included patients with duration\3 months
Fraser 1982 Included patients with duration\3 months
Javid 1983 Included patients with duration\3 months
Feldman 1986 Duration of LBP not reported
Dabezies 1988 Duration of LBP not reported
Ejeskar 1983 Duration of LBP not reported
Crawshaw 1984 Duration of LBP not reported
Lavignolle 1987 Duration of LBP not reported
Muralikuttan 1992 Included patients with duration\3 months
Benoist 1993 Duration of LBP not reported
Hedtmann 1992 Duration of LBP not reported
Bourgeois 1988 Included patients with duration\3 months
Bontoux 1990 Included patients with duration\3 months
Bromley 1984 Included patients with duration\3 months
Yu 1996 Article in Chinese/Mandarin
Steffen 1996 Included patients with duration\3 months
Revel 1993 Included patients with duration\3 months
Abdi 2007 Wilson-McDonald 2005 Duration of LBP not reported
Arden 2005 Included patients with duration\3 months
Carette 1997 Included patients with duration\3 months
McGregor 2001 Duration of LBP not reported
Pirbudak 2003 No comparisons with injection therapy
Snoek 1977 Included patients with duration\3 months
Cuckler 1985 Duration of LBP not reported
Dilke 1973 Included patients with duration\3 months
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Review Study Reason for exclusion
Ridley 1988 Duration of LBP not reported
Rogers 1992 Duration of LBP not reported
Kraemer 1997 Duration of LBP not reported
Riew 2006 Duration of LBP not reported
Ng 2005 Duration of LBP not reported
Karppinen 2001 Included patients with duration\3 months
Vad 2002 Included patients with duration\3 months
Devulder 1999 Duration of LBP not reported
Thomas 2003 Included patients with duration\3 months
Bush 1991 Included patients with duration\3 months
Matthews 1987 Included patients with duration\3 months
Helsa 1979 Article in Norwegian
Meadeb 2001 Included patients with duration\3 months
Chou 2009 Hameroff 1981 Duration of LBP not reported
Dechow 1999 Outside the scope of this review (prolotherapy)
Klein 1993 Outside the scope of this review (prolotherapy)
Ongley 1987 Outside the scope of this review (prolotherapy)
Yelland 2004 Outside the scope of this review (prolotherapy)
Ackerman 2007 Included patients with duration\3 months
Bonetti 2005 Included patients with duration\3 months
Fukusaki 1998 Included patients with duration\3 months
Gallucci 2007 Included patients with duration\3 months
Jeong 2007 Included patients with duration\3 months
Manchikanti 2004 No injection therapy comparison
Helliwell 1985 Included patients with duration\3 months
Klenerman 1984 All patients had acute sciatica (\6 weeks duration)
Zahaar 1991 Included patients with duration\3 months
Buchner 2000 Included patients with duration\3 months
Butterman 2004 Included patients with duration\3 months
Kolsi 2000 Included patients with duration\3 months
Pirbudak 2003b Included patients with duration\3 months
Nash 1989 Duration of LBP not reported
Luukkainen 2002 Duration of LBP not reported
Buttermann 2004 Patients randomized to surgery, not injection therapy
Graham 1975 Included patients with duration\3 months
Khot 2004 Duration of LBP not reported
Simmons 1992 Duration of LBP not reported
Graham 1976 Included patients with duration\3 months
Hoogland 2006 All subjects underwent endoscopic discectomy
Wittenberg 2001 Duration of LBP not reported
Burton 2000 Duration of LBP not reported
Krugluger 2000 Duration of LBP not reported
Steffen 1997 Included patients with duration\3 months
Sanders 1999 No injection therapy comparison
Kumar 2007 All patients had failed back surgery
North 2005 All patients had failed back surgery
a Studies in this review regarding surgery are not listed
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Table 5 Forest plots and GRADE evidence proﬁles
Analysis 01.01   IDET vs. placebo for chronic non-specific LBP, Change in pain intensity from baseline on 
SF-36 Bodily Pain Index (100-point). Long term follow up (6 months). 
Study or Subgroup
Freeman 2005
Pauza 2001
Total (95% CI)
Heterogeneity: Chi² = 0.09, df = 1 (P = 0.76); I² = 0%
Test for overall effect: Z = 2.16 (P = 0.03)
Mean
-38.28
-53
SD
21.37
19
Total
36
32
68
Mean
-31.47
-44
SD
15.29
20
Total
19
24
43
Weight
52.8%
47.2%
100.0%
IV, Fixed, 95% CI
-6.81 [-16.61, 2.99]
-9.00 [-19.36, 1.36]
-7.84 [-14.96, -0.72]
IDET Placebo Mean Difference Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours IDET Favours placebo
Analysis 01.02   IDET vs. placebo for chronic non-specific LBP, Change in functional status from baseline 
on Oswestry Disability Index (100-point). Long term follow up (6 months). 
Study or Subgroup
Freeman 2005
Pauza 2001
Total (95% CI)
Heterogeneity: Chi² = 1.37, df = 1 (P = 0.24); I² = 27%
Test for overall effect: Z = 1.86 (P = 0.06)
Mean
39.77
20
SD
16.28
12
Total
36
32
68
Mean
41.58
28
SD
11.29
15
Total
19
24
43
Weight
49.6%
50.4%
100.0%
IV, Fixed, 95% CI
-1.81 [-9.16, 5.54]
-8.00 [-15.30, -0.70]
-4.93 [-10.11, 0.25]
IDET Placebo Mean Difference Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours IDET Favours placebo
GRADE evidence profile (Analyses 01.01, 01.02) 
Date: 2009-07-01 
Question: Should IDET vs. placebo be used for chronic LBP? 
Quality assessment 
Summary of findings 
Importance
No of 
patients  Effect 
Quality
No of 
studies  Design Limitations Inconsistency Indirectness Imprecision Other 
considerationsIDETplacebo
Relative
(95% 
CI) 
Absolute 
Pain (follow-up 6 months; measured with: SF-36 Bodily Pain Index; range of scores: 0-100; Better indicated by lower values) 
2 randomised 
trials 
no serious 
limitations 
no serious 
inconsistency
serious
1 serious none 
68 43  - 
MD 7.84 
lower
(14.96 
lower to 
0.72 
lower)
⊕⊕ΟΟ
LOW 
Functional status (follow-up 6 months; measured with: Oswestry Disability Index; range of scores: 0-100; Better indicated by lower 
values) 
2 randomised 
trials 
no serious 
limitations 
no serious 
inconsistency
serious
1 serious
2 none 
68 43  - 
MD 4.93 
lower
(10.11 
lower to 
0.25 
higher) 
⊕⊕ΟΟ
LOW 
a Both studies included only patients with a positive response to provocative discography 
b Small sample size
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Analysis 02.02   Radiofrequency denervation of facet joints vs. placebo for chronic non-specific LBP, 
Change in pain intensity from baseline on pain VAS (100-point). Intermediate term follow 
up (1- 6 months). 
Study or Subgroup
van Kleef  1999
van Wijk 2005
Total (95% CI)
Heterogeneity: Tau² = 48.34; Chi² = 1.75, df = 1 (P = 0.19); I² = 43%
Test for overall effect: Z = 1.37 (P = 0.17)
Mean
-24
-21
SD
29
18
Total
15
40
55
Mean
-4
-16
SD
30
18
Total
16
41
57
Weight
28.6%
71.4%
100.0%
IV, Random, 95% CI
-20.00 [-40.77, 0.77]
-5.00 [-12.84, 2.84]
-9.29 [-22.57, 4.00]
Denervation Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours denervation Favours placebo
Analysis 02.03   Radiofrequency denervation of facet joints vs. placebo for chronic non-specific LBP, 
Change in pain intensity from baseline on pain VAS (100-point). Long term follow up (6 
months). 
Study or Subgroup
Gallagher 1994
Nath 2008
Tekin 2007
Tekin 2007
Total (95% CI)
Heterogeneity: Tau² = 20.71; Chi² = 4.58, df = 3 (P = 0.21); I² = 34%
Test for overall effect: Z = 1.77 (P = 0.08)
Mean
44
38.8
29
23
SD
30.55
48.6
16
13
Total
18
20
20
20
78
Mean
70
36.8
31
31
SD
29.44
48.6
8
8
Total
12
20
10
10
52
Weight
10.8%
6.1%
39.2%
44.0%
100.0%
IV, Random, 95% CI
-26.00 [-47.83, -4.17]
2.00 [-28.12, 32.12]
-2.00 [-10.59, 6.59]
-8.00 [-15.55, -0.45]
-6.99 [-14.73, 0.76]
Denervation Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours denervation Favours placebo
Analysis 02.04   Radiofrequency denervation of facet joints vs. placebo for chronic non-specific LBP, 
Change in functional status from baseline on Oswestry Disability Index (100-point). Short 
term follow up (≤4 weeks). 
Study or Subgroup
Tekin 2007
Tekin 2007
Total (95% CI)
Heterogeneity: Chi² = 0.14, df = 1 (P = 0.71); I² = 0%
Test for overall effect: Z = 3.46 (P = 0.0005)
Mean
24.4
25.6
SD
5.7
6.5
Total
20
20
40
Mean
30.5
30.5
SD
5.7
5.7
Total
10
10
20
Weight
52.4%
47.6%
100.0%
IV, Fixed, 95% CI
-6.10 [-10.43, -1.77]
-4.90 [-9.44, -0.36]
-5.53 [-8.66, -2.40]
Denervation Placebo Mean Difference Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours denervation Favours placebo
Analysis 02.01   Radiofrequency denervation of facet joints vs. placebo for chronic non-specific LBP, 
Change in pain intensity from baseline on pain VAS (100-point). Short term follow up (  4 
weeks). 
Study or Subgroup
Gallagher 1994
Tekin 2007
Tekin 2007
Total (95% CI)
Heterogeneity: Chi² = 1.07, df = 2 (P = 0.59); I² = 0%
Test for overall effect: Z = 5.87 (P < 0.00001)
Mean
34
28
23
SD
29.27
15
14
Total
18
20
20
58
Mean
60
43
43
SD
33.95
10
10
Total
12
10
10
32
Weight
6.7%
45.0%
48.3%
100.0%
IV, Fixed, 95% CI
-26.00 [-49.49, -2.51]
-15.00 [-24.03, -5.97]
-20.00 [-28.72, -11.28]
-18.15 [-24.21, -12.09]
Experimental Control Mean Difference Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours denervation Favours placebo
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c Single RCT, by definition is inconsistent
1448 Eur Spine J (2010) 19:1425–1449
12316. Fuchs S, Erbe T, Fischer HL, Tibesku CO (2005) Intraarticular
hyaluronic acid versus glucocorticoid injections for nonradicular
pain in the lumbar spine. J Vasc Interv Radiol 16(11):1493–1498
17. Manchikanti L, Pampati V, Bakhit C, Rivera JJ, Beyer CD,
Damron KS et al (2001) Effectiveness of lumbar facet joint nerve
blocks in chronic low back pain: a randomized clinical trial. Pain
Physician 4(1):101–107
18. Manchikanti L, Singh V, Falco FJE, Cash KA, Pampati V (2008)
Lumbar facet joint nerve blocks in managing chronic facet joint
pain: one-year follow-up of a randomized, double-blind controlled
trial: clinical trial NCT00355914. Pain Physician 11:121–132
19. Marks RC, Houston T, Thulbourne T (1992) Facet joint injection
and facet nerve block: a randomised comparison in 86 patients
with chronic low back pain. Pain 49(3):325–328
20. Dashﬁeld AK, Taylor MB, Cleaver JS et al (2005) Comparison of
caudal steroid epidural with targeted steroid placement during
spinal endoscopy for chronic sciatica: a prospective, randomized,
double-blind trial. Br J Anaesth 94:514–519
21. Serrao JM, Marks RL, Morley SJ, Goodchild CS (1992) Intra-
thecal midazolam for the treatment of chronic mechanical low
back pain: a controlled comparison with epidural steroid in a pilot
study. Pain 48(1):5–12
22. Lierz P, Gustorff B, Markow G, Felleiter P (2004) Comparison
between bupivacaine 0.125% and ropivacaine 0.2% for epidural
administration to outpatients with chronic low back pain. Eur J
Anaesthesiol 21(1):32–37
23. Mauro GL, Martorana U, Cataldo P, Brancato G, Letizia G
(2000) Vitamin B12 in low back pain: a randomised, double-
blind placebo-controlled study. Eur Rev Med Pharmacol Sci
4(3):53–58
24. Foster L, Clapp L, Erickson M et al (2001) Botulinum toxin A
and chronic low back pain: a randomized, double-blind study.
Neurology 56:1290–1293
25. Barendse GA, van Den Berg SG, Kessels AH et al (2001) Ran-
domized controlled trial of percutaneous intradiscal radiofre-
quency thermocoagulation for chronic discogenic back pain.
Spine 26:287–292
26. Ercelen O, Bulutcu E, Oktenoglu T et al (2003) Radiofrequency
lesioning using two different time modalities for the treatment of
lumbar discogenic pain: a randomized trial. Spine 28:1922–1927
27. Freeman BJ, Fraser RD, Cain CM et al (2005) A randomized,
double-blind, controlled trial: intradiscal electrothermal therapy
versus placebo for the treatment of chronic discogenic low back
pain. Spine 30:2369–2377
28. Kvarstein G, Ma ˚we L, Indahl A, Hol PC, Tennøe B, Digernes R,
Stubhaug A, Tønnessen TI, Beivik H (2009) A randomized
double-blind controlled trial of intra-annular radiofrequency
thermal disc therapy—a 12-month follow-up. Pain 145:279–286
29. Pauza KJ, Howell S, Dreyfuss P et al (2004) A randomized,
placebo-controlled trial of intradiscal electrothermal therapy for
the treatment of discogenic low back pain. Spine J 4:27–35
30. Oh WS, Shim JC (2004) A randomized controlled trial of
radiofrequency denervation of the ramus communicans nerve for
chronic discogenic low back pain. Clin J Pain 20(1):55–60
31. Gallagher J, Petriccione D, Wedley J et al (1994) Radiofrequency
facet joint denervation in the treatment of low back pain: a pro-
spective controlled double-blind study to assess its efﬁcacy. Pain
Clin 7:193–198
32. Leclaire R, Fortin L, Lambert R et al (2001) Radiofrequency
facet joint denervation in the treatment of low back pain: a pla-
cebo-controlled clinical trial to assess efﬁcacy. Spine 26:1411–
1416
33. Nath S, Nath C, Pettersson K (2008) Percutaneous lumbar zyg-
apophysial (facet) joint neurotomy using radiofrequency current,
in the management of chronic low back pain. Spine 33:1291–
1297
34. Tekin I, Mirzai H, OK G et al (2007) A comparison of conven-
tional and pulsed radiofrequency denervation in the treatment of
chronic facet joint pain. Clin J Pain 23:524–529
35. van Kleef M, Barendse G, Kessels A et al (1999) Randomized
trial of radiofrequency lumbar facet denervation for chronic low
back pain. Spine 24:1937–1942
36. van Wijk R, Geurts J, Wynne H et al (2005) Radiofrequency
denervation of lumbar facet joints in the treatment of chronic low
back pain: a randomized, double-blind, sham lesion-controlled
trial. Clin J Pain 21:335–344
37. Geurts J, van Wijk RM, Wynne HJ et al (2003) Radiofrequency
lesioning of dorsal root ganglia for chronic lumbosacral radicular
pain: a randomised, double-blind, controlled trial. Lancet
361:21–26
38. Egger M, Smith GD (1998) Meta-analysis bias in location and
selection of studies. BMJ 316:61–66
Eur Spine J (2010) 19:1425–1449 1449
123